{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:16:43Z","timestamp":1787671003978,"version":"build-2736575974"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tuberculosis (TB) remains the leading cause of death among people with human immunodeficiency virus (PWH). The diagnosis of latent TB infection (LTBI) and treatment with TB preventative therapy (TPT) can reduce morbidity and mortality in this population. Historically, isoniazid has been recommended for TPT in PWH due to the absence of drug-drug interactions with most antiretroviral therapy (ART). However, newer rifamycin-based regimens are safer, shorter in duration, associated with improved adherence, and may be as or more effective than isoniazid TPT. Current guidelines have significant heterogeneity in their recommendations for TPT regimens and acceptability of drug interactions with modern ART. In this Infectious Diseases learning unit, we review common questions on diagnosis, treatment, and drug interactions related to the management of LTBI among PWH.<\/jats:p>","DOI":"10.1093\/ofid\/ofab319","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T16:09:45Z","timestamp":1626538185000},"source":"Crossref","is-referenced-by-count":3,"title":["Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"8","author":[{"given":"Nicky J","family":"Mehtani","sequence":"first","affiliation":[{"name":"University of California, San Francisco, Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Puryear","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pham","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Department of Medicine, Division of Clinical Pharmacology, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maunank","family":"Shah","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"2021081308033692900_CIT0001","volume-title":"WHO consolidated guidelines on tuberculosis. Module 1: Prevention \u2013 Tuberculosis preventive treatment","author":"World Health Organization","year":"2020"},{"key":"2021081308033692900_CIT0002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Clinical practice. Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0003","first-page":"213","article-title":"Immunology of tuberculosis","volume":"120","author":"Raja","year":"2004","journal-title":"Indian J Med Res"},{"issue":"RR-6","key":"2021081308033692900_CIT0004","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"ATS\/CDC\/IDSA","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2021081308033692900_CIT0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1164\/rccm.2508001","article-title":"Controlling tuberculosis in the United States","volume":"172","author":"ATS\/CDC\/IDSA","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2021081308033692900_CIT0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"key":"2021081308033692900_CIT0007","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0008","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jama.1992.03490040080029","article-title":"High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy","volume":"268","author":"Selwyn","year":"1992","journal-title":"JAMA"},{"key":"2021081308033692900_CIT0009","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-119-3-199308010-00003","article-title":"Risk for developing tuberculosis among anergic patients infected with HIV","volume":"119","author":"Moreno","year":"1993","journal-title":"Ann Intern Med"},{"key":"2021081308033692900_CIT0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.1995.03530020061033","article-title":"Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA)","volume":"274","author":"Antonucci","year":"1995","journal-title":"JAMA"},{"key":"2021081308033692900_CIT0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-126-2-199701150-00005","article-title":"Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group","volume":"126","author":"Markowitz","year":"1997","journal-title":"Ann Intern Med"},{"key":"2021081308033692900_CIT0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2021081308033692900_CIT0013","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw694","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021081308033692900_CIT0014","author":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV"},{"key":"2021081308033692900_CIT0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hiv.12878","article-title":"2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0","volume":"21","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"2021081308033692900_CIT0016","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/00002030-200305020-00027","article-title":"Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy","volume":"17","author":"Fisk","year":"2003","journal-title":"AIDS"},{"key":"2021081308033692900_CIT0017","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/00002030-200209270-00021","article-title":"High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy","volume":"16","author":"Girardi","year":"2002","journal-title":"AIDS"},{"key":"2021081308033692900_CIT0018","author":"World Health Organization.","year":"2015"},{"key":"2021081308033692900_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2021081308033692900_CIT0020","author":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2021081308033692900_CIT0021","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2021081308033692900_CIT0022","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Temprano ANRS Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.200410-1342OC","article-title":"Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan","volume":"172","author":"Seyler","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2021081308033692900_CIT0024","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Insight Start Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0025","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"Badje","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2021081308033692900_CIT0026","doi-asserted-by":"crossref","first-page":"e0142290","DOI":"10.1371\/journal.pone.0142290","article-title":"Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials","volume":"10","author":"Ayele","year":"2015","journal-title":"PLoS One"},{"key":"2021081308033692900_CIT0027","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2021081308033692900_CIT0028","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"2021081308033692900_CIT0029","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"key":"2021081308033692900_CIT0030","first-page":"76","article-title":"Cultural case management of latent tuberculosis infection","volume":"8","author":"Goldberg","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021081308033692900_CIT0031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0032","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021081308033692900_CIT0033","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0034","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","article-title":"Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults","volume":"15","author":"Johnson","year":"2001","journal-title":"AIDS"},{"key":"2021081308033692900_CIT0035","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0036","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"2021081308033692900_CIT0037","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"2021081308033692900_CIT0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0039","author":"Farenc"},{"key":"2021081308033692900_CIT0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021081308033692900_CIT0041","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2021081308033692900_CIT0042","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2021081308033692900_CIT0043","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","article-title":"Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"2021081308033692900_CIT0044","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City","volume":"14","author":"Li","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2021081308033692900_CIT0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2021081308033692900_CIT0046","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081308033692900_CIT0047","author":"Ebrahim"},{"key":"2021081308033692900_CIT0048","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.01598-10","article-title":"Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets","volume":"55","author":"Decloedt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081308033692900_CIT0049","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"key":"2021081308033692900_CIT0050","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.eye.6703016","article-title":"Uveitis associated with concurrent administration of rifabutin and lopinavir\/ritonavir (Kaletra)","volume":"21","author":"Lin","year":"2007","journal-title":"Eye (Lond)"},{"key":"2021081308033692900_CIT0051","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jac\/dkz068","article-title":"Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide","volume":"74","author":"Cerrone","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021081308033692900_CIT0052","article-title":"Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection","author":"Custodio","journal-title":"EACS"},{"key":"2021081308033692900_CIT0053","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2021081308033692900_CIT0054","author":"Arora"},{"key":"2021081308033692900_CIT0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021081308033692900_CIT0056","first-page":"549","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021081308033692900_CIT0057","author":"Custodio"},{"key":"2021081308033692900_CIT0058","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase \u00bd trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2021081308033692900_CIT0059","author":"ClinicalTrials.gov","year":"2019"},{"key":"2021081308033692900_CIT0060","author":"Sun"},{"key":"2021081308033692900_CIT0061","author":"Liverpool Drug Interactions Group"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab319\/39073826\/ofab319.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/8\/ofab319\/39715640\/ofab319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/8\/ofab319\/39715640\/ofab319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T08:09:22Z","timestamp":1628842162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab319\/6323324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab319","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,7,17]]},"article-number":"ofab319"}}